# Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection

> **NCT03205566** · PHASE4 · COMPLETED · sponsor: **Guy's and St Thomas' NHS Foundation Trust** · enrollment: 38 (actual)

## Conditions studied

- Hiv

## Interventions

- **DRUG:** Raltegravir 400Mg Tab
- **DRUG:** Lamivudine 150Mg Tablet

## Key facts

- **NCT ID:** NCT03205566
- **Lead sponsor:** Guy's and St Thomas' NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03205566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03205566, "Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03205566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*